NRBO neurobopharma.com Company Profit

NRBO (NeuroBo Pharmaceuticals, Inc.) - company brandmark

NeuroBo Pharmaceuticals (NRBO) is expanding its portfolio of treatments for MASH and metabolic disorders to capture the neuropharmaceutical segment. The company's profit volume demonstrates current financial stability, with the indicator standing at -0.03. Future revenues depend on the efficacy of new molecules in obesity therapy; however, geopolitical tensions and sanctions are currently hindering international trials and the logistics of biomaterials.

Net Income: NeuroBo (NRBO) for 07/04/2022 - 12/07/2024

Analytical breakdowns and data insights for company NeuroBo Pharmaceuticals, Inc. (NRBO)

- stock value and consensus price forecast:
Market Price NeuroBo Pharma|NRBO - Price Target Chart
- market capitalization data:
Market Capitalization NeuroBo Pharma|NRBO - Enterprise Value
- book capitalization information:
Net Asset Value per Share NeuroBo Pharmaceuticals|NRBO - Company Net Assets|Market Capitalization to Book Value Ratio neurobopharma.com|NRBO - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio NeuroBo Pharmaceuticals|NRBO - Long-Term Debt to Equity|Current Liabilities to Capital NeuroBo Pharmaceuticals Inc|NRBO - Company Aggregate Debts|Debt to Book Capitalization Ratio NeuroBo Pharma|NRBO - Company Long-Term Debt|Short-Term Debt NeuroBo Pharmaceuticals|Intermediate Coverage Ratio neurobopharma.com
- company profitability and valuation multiples indicators:
NRBO - Company Net Income
Fundamental valuation:NeuroBo Pharma, NRBO
Manufactured products of NeuroBo Pharmaceuticals

To minimize risks when selecting an issuer, it is critical to track the difference between total revenues and all business operating expenses. Analyzing the operating profit of NeuroBo Pharmaceuticals (NRBO) allows for an assessment of cost management efficiency, which is particularly significant for NeuroBo Pharmaceuticals as it scales R&D projects for the treatment of neurodegenerative pathologies and steatohepatitis, where high margins serve as the primary bulwark against bankruptcy.

Main competitors

Company Net Income Biogen Idec (BIIB)|Company Net Income Neurocrine Biosciences|Company Profit RGC (regencellbioscience.com)|Net Profit AXSM|ACAD - Company Net Income|Xenon Pharmaceuticals Inc - Net Income|Net Profit Viking Therapeutics Corp VKTX|SUPN - Company Net Income|Final Profit CPRX (catalystpharma.com)|Denali Therapeutics Inc. (DNLI) - Company Net Income|Company Net Income Harmony Biosciences Inc (HRMY)|BHVN (Biohaven Pharmaceutical) - Net Profit|Company Net Income AMLX|Company Net Income Trevi Therapeutics (TRVI)|PRAX - Company Net Income|Anavex Life Sciences Corp. - Net Income|Final Profit CBLL|PRTA - Company Net Income|Profit After Tax ALEC|ANNX: Net Profit|Omeros - Final Profit|NGNE (Neurogene) - Net Profit|Net Profit AC Immune S.A.|Company Net Income Voyager Pharma (VYGR)|NMRA (Neumora Corp) - Final Profit|Company Net Income Scilex Holding Company SCLX|TVGN - Net Income|Alpha Cognition Corp - Net Profit|CGTX - Net Profit|IKT: Net Profit|Net Income Cassava Pharma|ASRT (Assertio Holdings) - Net Profit|Company Net Income Coya COYA|Net Income VTGN (Vistagen Therapeutics)|Net Profit ovidrx.com (OVID)|Acumen Pharma - Net Income|Profit After Payment of Taxes CRVO (CervoMed Corporation)|Alterity Therapeutics Ltd - Net Profit|Net Financial Result Clene Inc. CLNN|PEPG: Net Profit|Net Income jupiterneurosciences.com|RLMD (Relmada) - Net Profit|Net Profit Annovis Bio Corporation|Company Net Income Grace Therapeutics, Inc. (GRCE)|Company Net Income AIFF (fireflyneuro.com)|Company Net Income Klotho Neurosciences KLTO|Net Financial Result NeuroSense Therapeutics Ltd (NRSN)|RVPH - Company Net Income|MTVA (MetaVia Inc) - Company Profit|NeurAxis, Inc. (NRXS) - Company Net Income|Helius Medical Technologies - Final Profit|PASG (Passage Bio Inc.) - Net Profit|Company Net Income NEUP|Company Net Income Minerva Neurosciences Corp (NERV)|ATHA - Company Net Income|Company Net Income Addex Therapeutics ADXN|ALZN: Company Profit|Cyclerion - Net Profit|Company Net Income Protagenic Therapeutics|KTTA (pasitheaclinics.com) - Net Income|Cortigent (CRGT) - Net Profit|Company Net Income Avenue Therapeutics|BCLI: Final Profit|Company Net Income Cara Therapeutics (CARA)|CHRO - Company Net Income|Company Net Income Eliem Therapeutics Inc. ELYM|ITCI: Company Profit|Longboard Pharmaceuticals - Net Profit|Company Net Income marinuspharma.com|NKGN (NKGen Biotech) - Net Income|Sage Therapeutics Inc. (SAGE) - Net Profit|Company Net Income Neurotrope|TRVN: Final Profit|Company Net Income Vigil Neuroscience (VIGL)|WENA - Company Net Income|Net Profit CERE (Cerevel Therapeutics, Inc.)